Business Context and Reporting Period
This Form 8-K is filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on December 27, 2024, regarding a notice of delisting from the Nasdaq Capital Market. The filing addresses the company's failure to meet the minimum bid price requirement and stockholders' equity standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures. However, it discloses the following financial status indicators:
- Stock Price: The closing bid price was below $1.00 per share for 33 consecutive business days.
- Stockholders' Equity: The company does not comply with the $4,000,000 to $5,000,000 minimum stockholders' equity initial listing requirement for Nasdaq.
- Liquidity/Debt: No specific debt or liquidity metrics are provided in this text.
Material Changes
The primary material change is the loss of compliance with Nasdaq listing standards:
- Delisting Notice: On December 27, 2024, Nasdaq notified the company that it failed to regain compliance with the Minimum Bid Price Requirement within the 180-day remediation period (ending December 26, 2024).
- Remediation Status: The company is not eligible for a second 180-day remediation period due to failing the stockholders' equity requirement.
- Listing Status: Securities are subject to suspension or delisting unless a hearing is requested.
Guidance, Outlook, and Risks
Management Actions and Outlook:
- Hearing Request: The company submitted a request for a hearing before a Hearings Panel on January 3, 2025, which automatically stays delisting action pending the outcome.
- Reverse Stock Split: A special meeting of stockholders is scheduled for January 31, 2025, to approve a reverse stock split with a ratio ranging from 1:2 to 1:30 to address the minimum bid price requirement.
Risks and Contingencies:
- There is no assurance the company will regain compliance with the Minimum Bid Price Requirement.
- There is no assurance the Hearings Panel will grant a suspension of delisting or continued listing.
- Even if the bid price requirement is met, there is no assurance the company can comply with other Nasdaq listing standards.
Investor Verification Checklist
- Verify the outcome of the hearing request submitted on January 3, 2025.
- Confirm the specific reverse stock split ratio approved at the January 31, 2025, special meeting.
- Monitor the company's stockholders' equity levels to ensure compliance with the $4M-$5M threshold.
- Check for any subsequent Nasdaq rulings regarding the suspension or delisting of ticker symbol TIVC.